HistoIndex and A*STAR Partner on Fibrosis Drug Evaluation

Oct 19, 2026
HistoIndex and A*STAR will use quantitative tissue analysis to evaluate therapeutic candidates for fibrotic diseases during preclinical research.

HistoIndex and Singapore's A*STAR signed a memorandum of understanding to evaluate therapeutic candidates for fibrotic diseases, including cancer associated fibrosis, the organizations said in a press release.

The collaboration combines A*STAR's therapeutic research capabilities with HistoIndex's imaging technology and AI based quantitative tissue analysis. Researchers will use the platform to measure fibrosis and treatment responses during preclinical evaluation, supporting decisions about which candidates to advance.

The organizations may also work together on biomarker discovery, translational research, therapeutic development and commercialization.

We hope you enjoyed this article

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.